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Background It is uncertain if elevated admission plasma glucose (APG) remains an independent determinant of longer-term mortality as the 
modern treatment of myocardial infarction (MI) is based on early restoration of coronary reperfusion by primary percutaneous coronary intervention 
(PCI).
Methods We studied 1185 consecutive MI pts in the separate years 1996, 1999 (pre-invasive era) and 2003, 2006 (invasive era). In both eras 
APG was derived according to a standard MI protocol. A model was created to study the relation between APG, reperfusion era and mortality.
Results During 5-year f-up, 261 pts (22%) had died. Mortality was lower in the invasive (19%) than in the pre-invasive era (28%), p <0.001. 
After adjustment for multiple confounders, increased APG was associated with increased mortality, irrespective of treatment era: each mmol/l APG 
increase corresponded with 7% increased mortality (adjusted hazard ratio [HR] 1.07; 95% confidence interval [CI] 1.04 to 1.10). Patients with an 
APG > 11 mmol/l had 2-fold higher mortality (HR 2.0 and 95% CI 1.4 to 2.7) than patients with a lower APG. No significant interaction between APG 
and treatment era for 5-yr mortality was found (p 0.08).
Conclusion Elevated APG is a strong determinant of 5-year mortality irrespective of the advances that have been made in reperfusion therapy. 
Every 1 mmol/l increase in APG raises mortality with 7%.
Whether immediate correction of this metabolic dysregulation improves clinical outcome remains to be determined.
